Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

αvβ3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26.

Nestić D, Uil TG, Ma J, Roy S, Vellinga J, Baker AH, Custers J, Majhen D.

J Virol. 2018 Dec 10;93(1). pii: e01474-18. doi: 10.1128/JVI.01474-18. Print 2019 Jan 1.

2.

Progress in Adenoviral Capsid-Display Vaccines.

Vujadinovic M, Vellinga J.

Biomedicines. 2018 Jul 26;6(3). pii: E81. doi: 10.3390/biomedicines6030081. Review.

3.

Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.

Vujadinovic M, Khan S, Oosterhuis K, Uil TG, Wunderlich K, Damman S, Boedhoe S, Verwilligen A, Knibbe J, Serroyen J, Schuitemaker H, Zahn R, Scheper G, Custers J, Vellinga J.

Vaccine. 2018 Jul 16;36(30):4462-4470. doi: 10.1016/j.vaccine.2018.06.024. Epub 2018 Jun 18.

4.

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Apr 24;13(4):e0196546. doi: 10.1371/journal.pone.0196546. eCollection 2018.

5.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Feb 20;13(2):e0192312. doi: 10.1371/journal.pone.0192312. eCollection 2018. Erratum in: PLoS One. 2018 Apr 24;13(4):e0196546.

6.

Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.

Çuburu N, Khan S, Thompson CD, Kim R, Vellinga J, Zahn R, Lowy DR, Scheper G, Schiller JT.

Int J Cancer. 2018 Apr 1;142(7):1467-1479. doi: 10.1002/ijc.31166. Epub 2017 Dec 1.

7.

Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Vujadinovic M, Wunderlich K, Callendret B, Koning M, Vermeulen M, Sanders B, van der Helm E, Gecgel A, Spek D, de Boer K, Stalknecht M, Serroyen J, Grazia Pau M, Schuitemaker H, Zahn R, Custers J, Vellinga J.

Hum Gene Ther. 2018 Mar;29(3):337-351. doi: 10.1089/hum.2017.023. Epub 2017 Nov 30.

8.

Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.

Salisch NC, Vujadinovic M, van der Helm E, Spek D, Vorthoren L, Serroyen J, Kuipers H, Schuitemaker H, Zahn R, Custers J, Vellinga J.

PLoS One. 2017 Mar 31;12(3):e0174728. doi: 10.1371/journal.pone.0174728. eCollection 2017.

9.

Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.

Khan S, Oosterhuis K, Wunderlich K, Bunnik EM, Bhaggoe M, Boedhoe S, Karia S, Steenbergen RDM, Bosch L, Serroyen J, Janssen S, Schuitemaker H, Vellinga J, Scheper G, Zahn R, Custers J.

Int J Cancer. 2017 Jul 15;141(2):393-404. doi: 10.1002/ijc.30679. Epub 2017 Apr 24.

10.

Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.

Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H.

Vaccine. 2015 Oct 5;33(41):5406-5414. doi: 10.1016/j.vaccine.2015.08.056. Epub 2015 Aug 28.

11.

An alternative to the adenovirus inverted terminal repeat sequence increases the viral genome replication rate and provides a selective advantage in vitro.

Wunderlich K, van der Helm E, Spek D, Vermeulen M, Gecgel A, Pau MG, Vellinga J, Custers J.

J Gen Virol. 2014 Jul;95(Pt 7):1574-84. doi: 10.1099/vir.0.064840-0. Epub 2014 Apr 24.

PMID:
24764357
12.

Challenges in manufacturing adenoviral vectors for global vaccine product deployment.

Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers J, Havenga M.

Hum Gene Ther. 2014 Apr;25(4):318-27. doi: 10.1089/hum.2014.007. Epub 2014 Apr 2. Review.

PMID:
24593243
13.

Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.

Zahn R, Gillisen G, Roos A, Koning M, van der Helm E, Spek D, Weijtens M, Grazia Pau M, Radošević K, Weverling GJ, Custers J, Vellinga J, Schuitemaker H, Goudsmit J, Rodríguez A.

PLoS One. 2012;7(12):e44115. doi: 10.1371/journal.pone.0044115. Epub 2012 Dec 6.

14.

Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling.

Pahl JH, Verhoeven DH, Kwappenberg KM, Vellinga J, Lankester AC, van Tol MJ, Schilham MW.

Mol Immunol. 2012 May;51(1):91-100. doi: 10.1016/j.molimm.2012.02.119. Epub 2012 Mar 16.

PMID:
22424784
15.

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.

16.

Directed adenovirus evolution using engineered mutator viral polymerases.

Uil TG, Vellinga J, de Vrij J, van den Hengel SK, Rabelink MJ, Cramer SJ, Eekels JJ, Ariyurek Y, van Galen M, Hoeben RC.

Nucleic Acids Res. 2011 Mar;39(5):e30. doi: 10.1093/nar/gkq1258. Epub 2010 Dec 7.

17.

A lentiviral vector-based adenovirus fiber-pseudotyping approach for expedited functional assessment of candidate retargeted fibers.

Uil TG, de Vrij J, Vellinga J, Rabelink MJ, Cramer SJ, Chan OY, Pugnali M, Magnusson M, Lindholm L, Boulanger P, Hoeben RC.

J Gene Med. 2009 Nov;11(11):990-1004. doi: 10.1002/jgm.1395.

PMID:
19757488
18.

Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice.

Schagen FH, Graat HC, Carette JE, Vellinga J, van Geer MA, Hoeben RC, Dermody TS, van Beusechem VW.

Hum Gene Ther. 2008 Aug;19(8):783-94. doi: 10.1089/hum.2007.133.

19.

A system for efficient generation of adenovirus protein IX-producing helper cell lines.

Vellinga J, Uil TG, de Vrij J, Rabelink MJ, Lindholm L, Hoeben RC.

J Gene Med. 2006 Feb;8(2):147-54.

PMID:
16288495
20.

The adenovirus capsid: major progress in minor proteins.

Vellinga J, Van der Heijdt S, Hoeben RC.

J Gen Virol. 2005 Jun;86(Pt 6):1581-8. Review.

PMID:
15914835

Supplemental Content

Loading ...
Support Center